Trial Profile
Quantitative PET Imaging of Pancreatic Beta-Cell Mass in Healthy Overweight/Obese Subjects, Subjects With Prediabetes, and Type 2 Diabetes Patients With 18F-FP-DTBZ (18F-AV-133)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Florbenazine F18 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 12 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2014 New trial record